AbbVie Inc (ABBV)vsThe Cooper Companies, Inc (COO)
ABBV
AbbVie Inc
$245.87
+0.89%
HEALTHCARE · Cap: $430.82B
COO
The Cooper Companies, Inc
$74.23
+1.24%
HEALTHCARE · Cap: $13.71B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1422% more annual revenue ($64.39B vs $4.23B). ABBV leads profitability with a 9.8% profit margin vs 5.6%. ABBV appears more attractively valued with a PEG of 0.41. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
COO
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$245.87
$94.97 premium
Margin of Safety
+59.9%
Fair Value
$206.89
Current Price
$74.23
$132.66 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 26.9% YoY
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
ROE of 2.9% — below average capital efficiency
5.6% margin — thin
Premium valuation, high expectations priced in
Operating margin of -2.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : COO
The strongest argument for COO centers on Debt/Equity, PEG Ratio, Price/Book. PEG of 0.69 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : COO
The primary concerns for COO are Return on Equity, Profit Margin, P/E Ratio. A P/E of 61.3x leaves little room for execution misses.
Key Dynamics to Monitor
COO carries more volatility with a beta of 0.84 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 59/100) and 10.2% revenue growth. COO offers better value entry with a 59.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
The Cooper Companies, Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?